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Abstract. Hyperprolactinaemia is one of the most frequent causes of anovulation, resulting in infertility and hypoestrogenic  
state with consequences on overall women’s health. Recent investigations on biological actions of prolactin, especially 
prolactin of extrapituitary origin, expand our knowledge  on prolactin role in the human organism and open new questions 
connected with female reproductive function and treatment of female infertility. This article represents the review of current 
knowledge on prolactin physiology, etiopathogenesis, clinical features, assessment , differential diagnosis ,and teatment of 
hyperprolactinaemia in the female patient. 
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Introduction 
Prolactin (PRL) was first discovered in the late 1920s 
by different authors who demonstrated the ability of the 
injected bovine pituitary extract to cause lactation in 
rabbits [1].  
The hormone was purified in 1932 by Riddle et al. 
and was named "pro-lactin" due to its it’s lactogenic ac-
tion [2].  
PRL was not able to be separated from growth hormone 
(GH) till 1970’s when adequate radioimmunoassay was 
developed by Friesen et al [3, 4].  
Today, PRL is known to act at many different tissues 
with numerous biological activities. Hyperprolactinae-
mia is one of the most common problems in human en-
docrinology, especially connected with reproduction. In 
fact, PRL is viewed as a hormone on a global level, but 
its paracrine/autocrine action as cytokine is also the sub-
ject of numerous investigations.    
Physiology of PRL Secretion 
PRL belongs to the PRL/GH/placental lactogen family. 
Those hormones share a similar structure, function, and 
binding properties, as well as the origin from a common 
ancestral gene from which they have diverged 400 mil-
lion years ago [5]. 
The prolactin gen is located on chromosome 6 in the 
human genome [6], with different promoter regions di-
recting pituitary and extrapituitary PRL synthesis, which 
is the unique characteristic of humans [7].  
This gene is encoding prohormone for prolactin, which 
is consisted of 227 amino acids, with a signaling peptide of 
28 amino acids. PRL is a polypeptide hormone, aminoacid 
chain consisting of 199 amino acids, 50% of them are in the 
form of α-helix and the rest forms the loop. The tertiary 
structure was predicted according to the current three-
dimensional model: prolactin contains four long α-helices, 
arranged in antiparallel fashion [5, 8].  
The molecular weight of PRL is around 23 kDa, 
which represents the main and biologically the most po-
tent form of PRL in circulation - monomeric or small 
PRL. There are also the variants of PRL molecule: 60 
kDa form – big PRL (dimmer) and big-big PRL of 150 – 
170 kDa. Posttranslational processing is taking place in 
the anterior pituitary, including polymerization, phos-
phorization, glycolysis as well as formatting complexes 
with immunoglobulins (the most often with IgG in hu-
mans) or forming covalent and noncovalent bonds [5]. 
Such macromolecular forms have clinical implications, 
which will be discussed later.  
PRL may have pituitary and extra-pituitary origin. 
The main sources of prolactin in humans are anterior pi-
tuitary lactotrophs. Synthesis and secretion of pituitary 
PRL are regulated by both inhibiting, and releasing fac-
tors (Table 1). Inhibiting factors include dopamine, 
gamma-aminobutyric acid (GABA) and somatostatin [5]. 
Hypothalamic dopamine is considered to be the main 
prolactin inhibiting factor in humans exerting its action 
through D2 and D4 receptors located on cell membranes 
of lactotrophs. Such dopamine action results in down-
regulation of PRL gene expression reduced PRL secre-
tion and decreased lactotroph proliferation [9]. 
Different molecules release pituitary prolactin (table 
1), thyrotropin-releasing hormone (TRH) being clinically 
the most important, but "PRL-releasing factor" has not 
been identified as it is the case for other pituitary hor-
mones [10]. 
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Pituitary PRL is secreted in a pulsatile fashion, with 
peaks  20–30 minutes apart. This fact has clinical impli-
cations: taking three samples in 20–30 min. apart could 
help to make the correct diagnosis of hyperprolactinae-
mia.  
Pituitary prolactin secretion is characterized by a 
unique circadian rhythm. Higher levels occur during the 
sleep, with two peaks: around 17-20h and higher one be-
tween 02h and 04 h (about 4–5 hours after the beginning 
of the sleep). These facts also have clinical implications: 
higher PRL levels during the sleep cause “nocturnal hy-
perprolactinaemia” and possible galactorrhoea, espe-
cially in chronic stress (Figure 1).  
PRL serum levels in humans are also fluctuating dur-
ing the menstrual cycle, increasing during the follicular 
phase with periovulatory peak [12], so it was recom-
mended to measure PRL serum levels in the early follic-
ular phase, as we do in our everyday clinical practice 
[13].  
Extra-pituitary prolactin is structurally identical to pi-
tuitary PRL. It is produced in the ovaries, uterus and en-
dometrium, breast, prostate, lymphocytes, haematopoetic 
cells, adipose tissue, skin, thymus, lymphatic system, en-
dothelium, and the brain. The action is still under inves-
tigation, the most probably autocrine/paracrine nature, 
but it was well established that its regulation is site- spe-
cific and quite different from the pituitary PRL [5, 14].  
Actions of PRL 
PRL acts through its receptor (PRL-R): a single mem-
brane- bound protein of the cytokine receptor family, ex-
pressed in the pituitary and in the numerous other tissues 
as the mammary gland, endometrium, ovaries, heart, 
lung, thymus, liver, pancreas, spleen adrenal gland, skel-
etal muscle, bone (osteoblasts), skin, and brain [5]. 
PRL has more than 80 functions and over 300 sepa-
rate biological activities, the most investigated are repro-
ductive and homeostatic activities [5].  
Reproductive action of PRL includes roles in mammo-
genesis, lactogenesis, and galactopoiesis (development and 
maturation of the breast during pregnancy, induction, and 
maintaining of lactation) as well as its role in follicular de-
velopment and maintenance of the corpus luteum (luteo-
thropic action of physiological levels of PRL) [15]. PRL is 
also involved in oogenesis and adequate implantation [15]. 
Table 1 PRL inhibiting and releasing factors 
PRL inhibiting factors 
 dopamine from hypothalamus 
 gamma-aminobutyric acid (GABA) 
 somatostatin 
 
PRL releasing factors 
thyrotropin-releasing hormone (TRH) vasoactive intestinal polypeptide (VIP) 
endogenous opioides neurotensin 
oxytocin  galanin 
vasopressin salsolino 
 serotonin 





Fig. 1 Day and night profile of PRL serum levels in our 
patient with so-called "normoprolactinaemic 
galactorrhoea" caused by nocturnal hyperprolacti-
naemia due to chronic stress (being refuge during 
the civil war). Morning PRL levels are within 
physiological limits, while nocturnal PRL serum 
levels are higher than normal (a). Galactorrhoea and 
nocturnal hyperprolactinaemia ceased after the 
normalization of the living conditions (b) [11].   
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The possible PRL role in spermatogenesis is sup-
ported by findings of male infertility in knock-out PRL-
R mice [9, 16].   
The reproductive role of PRL is connected to its ac-
tion as brain neuropeptide: animal experiments showed 
that reproductive behaviour was under the influence of 
PRL, which could stimulate sexual receptivity during the 
estrus [17], while inhibited sexual behaviour during the 
lactation [18]. 
As brain neuropeptide, PRL also has a role in mediat-
ing the positive influence of social interactions between 
mother and child or between mating partners on the men-
tal and physical state and beneficial effects of such inter-
actions on adaptive processes related to emotional and 
physiological stress coping in both sexes [19]. 
PRL is also known as "stress hormone": increases se-
cretion of ACTH, induces adrenal hypertrophy and stor-
age of cholesterol esters, and stimulates the secretion of 
androgens (inclouding DHEA), cortisol, and aldosterone 
in adrenals [12]. 
Extrapituitary PRL acts as a cytokine on numerous 
sites. PRL produced by lymphocytes and haematpoietic 
cells is supposed to be involved in the immune response 
to stress [5, 12, 14, 20]. 
PRL promotes bone growth and mineralization in foe-
tus, whereas it is involved in bone resorption in preg-
nancy, providing micronutrients to foetus [21]. 
PRL has vasoconstrictive action and a possible role in 
the development of pre-eclampsia or peripartal cardio-
myopathy [15]. 
During the pregnancy, PRL is supposed to be in-
cluded in fetal osmoregulation and  inhibiting water 
transport across the human amnion [22]. 
Numerous actions of the extrapituitary PRL are still 
under investigation. The PRL roles in human physiology 
are illustrated in  the best way by the following words [5]: 
"It has been well recognized that prolactin ensures sur-
vival of the species through its reproductive role and sur-
vival of the individuals of the species in its homeostatic 
roles. While we know a great deal about the chemistry, 
biological actions, and controls in its reproductive role, 
there is a paucity of similar information in its homeo-
static roles".  
Etiopathogenesis  of Hyperprolactinaemia 
Hyperprolactinaemia could be physiological, pathological, 
and iatrogenic. The main causes of hyperprolactinaemia are 
listed in  the Table 2.  
Physiological causes could elevate PRL synthesis and 
release in  different manners. 
Endogenous oestrogens enhance PRL secretion by 
regulation of PRL gene expression, downregulation of 
dopamine receptor expression, and stimulation of lacto-
troph cell hyperplasia [5].  
During the pregnancy PRL serum levels progressively 
rises to 4 000 – 10 000 mIU/l (200 – 500 ng/ml) [23]. 
Suckling – induced PRL release during breastfeeding 
is caused by lowered dopamine tonus, but PRL releasing 
factors as TRH, oxytocin, etc (Table 1) are also proposed 
to be involved [5, 24].    
Neural mechanisms interfering with dopamine trans-
mission are involved in PRL release during the suckling 
in lactation and nipple stimulation [5], which is not ob-
served during the breast examination, breast ultrasound, 
or mammography. [25-27]. 
Table 2 Etiology of hyperprolactinaemia 
Physiological hyperpoalctinaemia: 
▪ pregnancy, puerperium and lactation, stress (psychic, 
physic, surgery and anaesthesia, hypoglicaemia etc), 
during the sleep, nipple stimulation and coitus, exercises 
and in 2.5% of healthy people,  
Pathological hyperpolactinaemia: 
▪ prolactinomas, other pituitary adenomas, and pituitary 
conditions (acromegaly, hypophysitis, 
macroprolactinaemia etc)   
▪ hypothalamic conditions and pituitary stalk compression 
(tumours, granulomas, infiltrative lesions, tuberculosis, 
sarcoidosis, cranial irradiation, trauma with stalk section, 
Rathke cleft cyst, craniopharyngiomas etc) 
▪ idiopathic hyperprolactinaemia 
▪ chronic renal failure 
▪ hypothyroidism 
▪ hepatic failure 
▪ chest: neurogenic chest wall trauma, surgery scars, herpes 
zoster  
▪ epileptic seizures 
▪ autoimmune diseases 
▪ 6-pyruvoyl tetrahydropterin synthase deficiency 
▪ ectopic PRL production by different tumours 
Pharmacological hyperprolactinaemia: 
▪ dopamine receptor antagonists and dopamine synthesis 
inhibitors   
▪ dopamine depleting agents (antihypertensives: methyl 
dopa, reserpine, verapamil, etc) 
▪ hormones and neuropeptides – stimulators of prolactin 
release (TRH, estrogens – oral contraceptives, etc)  
▪ opiates and opiate antagonists, morphine derivatives, 
aesthetics, opium smoking, opioid     addiction, cocaine 
and marijuana 
▪ antihistamines H2 (cimetidine, meclizine, etc)  
▪ antipsychotics / neuroleptics, antidepressants, 
anticonvulsants,  
▪ antiemmetics (domperidone and metoclopramide) 
▪ cholinergic agonist 
▪ catecholamine depletor 
Oral contraceptives containing high doses of oestro-
gen (>= 35 mcg) could rise PRL serum levels by altera-
tion of dopamine regulation [28], which is not a case  
with modern contraceptives with lower amounts of oes-
trogen [29]. 
Stress-induced changes in dopamine and serotonin 
may affect PRL release causing hyperprolactinaemia [20]  
It was already mentioned that hypothalamic dopa-
mine acts through D2 receptors on lactotrophs as the 
main PRL inhibiting factor. Therefore, the main reasons 
for elevated serum PRL levels in pathological and phar-
macological could be as follows:   
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▪ high PRL production (by prolactinoma),  
▪ disruption of the dopamine transport to the pitui-
tary (due to stalk compression by tumours or in-
flammation), 
▪ decreased dopamine PRL inhibition and elevated 
estrogen levels in hepatic failure, 
▪ decreased PRL clearance and increased PRL se-
cretion in renal failure,  
▪ blockade of endogenous dopamine receptors by a 
variety of drugs, 
▪ PRL synthesis stimulated by medications.    
Clinical Features of Hyperprolactinaemia 
Hyperprolactinaemia causes hypogonadism in women 
and men. Syndrome "galactorrhoea – amenorrhoea" was 
first described by Hypocrite. Women with hyperprolacti-
naemia could experience cycle irregularity (amenorrhoea 
and  oligomenorrhoea) or even to have regular cycles, but 
the consequence is infertility in the most. In fact, hy-
perprolactinaemia disturbed ovulation in women: on one 
end of the spectrum of the ovulation disorders caused by 
hyperprolactinaemia is amenorrhoea due to complete 
anovulation; on another end of the spectrum is luteal 
phase deficiency in women with almost regular cycles, 
but still with the problem to conceive. 
Hyperprolactinaemia in women could cause the de-
velopment of the hypoestrogenic state resulting in osteo-
porosis. In fact, hyperprolactinaemia could increase bone 
resorption and inhibits bone formation, both in men and 
women [30].  
Such hypoestrogenemic state is also associated with 
multiple impairement of female sexual functions (sexual 
desire and arousal, lubrication, orgasm, sexual satisfac-
tion, and dyspareunia) [31].  
Galactorrhoea is present in 10% to 90% of hyperpro-
lactinaemic women and in 14 – 33% of men [32].  Nipple 
discharge could be colorless, yellowish, white like breast 
milk in lactation or even dark. "Normoprolactinaemic 
galactorrhoea" is a condition characterized by  galactor-
rhoea associated with normal PRL serum levels meas-
ured in usual fashion. Nocturnal hyperprolactinaemia is 
a possible reason for that condition, for diagnostic pur-
poses day-night prolactin profile should be obtained (Fig-
ure 1).  
Hyperandogenemia could be present in 25% of hy-
perprolactinaemic women, due to the increase in adrenal 
DHEA, the consequence is mild hirsutism. Hyperandro-
genemia could be also present in patients with prolacti-
nomas [33].   
The connection between hyperprolactinaemia and fe-
male pattern hair loss is still unclear [34], but we have 
seen such cases in our own clinical practice. 
In men, hyperprolactinaemia causes hypogonadism: 
impotency, loss of libido ,and gynecomastia. Anaemia, 
decreased energy and muscle mass may be also present 
as secondary manifestations of hypogonadism [35, 36]. 
Abnormal pituitary findings were found in 50-80% of 
patients with monomeric hyperprolactinaemia [37]. Pro-
lactinomas are the main causes of hyperpolactinaemia 
and the most common type of pituitary adenomas (about 
40%) [38].  
In patients with prolactinomas, neurological manifes-
tations are present in cases with macroprolactinomas (pi-
tuitary adenoma > 10 mm in diameter): visual disturb-
ances if the tumor compresses optical chiasma, which is 
not the case with microprolactinoma (pituitary adenoma 
< 10 mm in diameter).   
The existence of hyperprolactinaemia was reported in 
numerous autoimmune disorders including: systemic lu-
pus erythematosus, rheumatoid arthritis, sclerodermia 
etc, which is explained by immunomodulatory effects of 
PRL acting as cytokine on the level of T- and B-lympho-
cytes, enhancing inflammatory response and immuno-
globulin production [39].   
Hyperprolactinaemia has a negative influence on gly-
coregulation, it was demonstrated that hyperpolactinae-
mia in patients with prolactinoma was associated with a 
higher risk of hyperglycaemia accompanied by obesity. 
Bromocriptine and cabergoline have favorable effects on 
glucose metabolism, but the exact mechanism of its ac-
tion on glycemic control and favorable cardio-metabolic 
profile is still unclear and it seems to be that this action is 
more complex than "the historical explanation of "reset-
ting" the circadian clock" [40].  
Metabolic consequences of dopamine agonists treat-
ment for hyperprolactinaemia  were investigated in 14 
consecutive patients with prolactinoma: insulin sensitiv-
ity tended to improve after 6 months of the treatment with 
dopamine agonists (bromocriptine and cabergoline) [41]. 
It was recommended that hyperprolactinaemic 
premenopausal women with abnormal lipide profile and 
positive familial history of coronary disease, should be 
subjects of investigation for hyperinsulinaemia, and if it 
exists, PRL serum levels and insulin resistance should be 
normalized by adequate therapy [42].    
Hyperprolactinaemia is also associated with endothe-
lial dysfunction, development of perimenopausal athero-
sclerosis, and risk for cardiovascular disease, probably 
connected with vasoconstrictive characteristics of prolac-
tin, but further studies are needed for definitive conclu-
sions [43].  
Osteoporosis could be developed in a hyperpro-
lactnaemic patient due to hypoestrogenemic state and de-
creased osteocalcin levels [44].   
It was also hypothesised  that multiple pregnancies 
and iatrogenic hyperpolactinaemia could increase the risk 
for otosclerosis [45].   
Hyperprolactinaemia and Female Infertility 
Hyperprolactinaemia causes anovulation and infertility. 
High PRL levels suppress GnRH (via reduction of kis-
speptins) and decrease LH pulse, ovarian oestrogens, and 
progesterone production [46, 47]. The consequences are 
menstrual irregularities (amenorrhoea or oligomenor-
rhoea), infertility, decreased libido, and galactorrhoea 
[38, 46]. 
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A novel hypothesis states that kisspeptin could be of 
crucial importance for the explanation of anovulation and 
infertility in hyperpolactinaemic state [48-50]. Kisspep-
tins, neuropeptides encoded by KISS1 gene, are potent 
stimulators of GnRH neurons and important for pubertal 
maturation and regulation of reproduction [50]. Kisspep-
tin is expressed in hypothalamic arcuate and anteroven-
tral periventricular nuclei. In the hyperprolactinaemic 
mouse model with continuous infusion of prolactin  sub-
cutaneously, the kisspeptin content was reduced and ad-
ministration of kisspeptin intraperitoneal injection once 
daily for 20 days restored estrous cyclicity, induced ovu-
lation, and increased LH and FSH levels in circulation 
[51]. Nevertheless, kisspeptins are not recommended for 
the therapy of amenorrhoea [52].  
 
 
Kisspeptin administered in brain chambers 
↓ 
Activity of tuberoinfudibular DA neurons are modulated 
↓ 





Scheme 1 Influence of kisspeptin on PRL release [53] 
 
  









Scheme 2 Influence of PRL on GnRH production [48, 
50, 54]. 
In the human ovary hyperprolactinaemia inhibits de-
velopment of corpus luteum, granulose cell luteinization, 
and steroidogenesis. PRL serum levels higher than 2000 
mIU/l (about 100 ng/ml) inhibit progesterone secretion 
[55, 56]. 
Women with PCOS have elevated PRL serum levels 
in 30% of cases, thought to be a consequence of elevated 
estrogen levels and reduction of dopamine tonus [57].   
However, the relationship between PCOS and hy-
perprolactinaemia remains unclear. Some authors stated 
that PCOS and hyperprolactinaemia are distinct entities 
[58, 59].  
Hyperprolactinaemia is reported to be present in pa-
tients with endometriosis, moreover, there was a positive 
correlation of serum prolactin levels and stadium of en-
dometriosis [60, 61]. 
Patients with endometriosis have exgaggerated  noc-
turnal PRL secretion, it was stated "this is the part of 
pathophysiology of that disease"  [62]. Human decidua 
produces prolactin and prolactin receptors are found in 
endometriotic tissue, therefore, it was postulated that the 
patients with endometriosis have at least occult hyperpro-
lactinaemia according to TRH (thyrotropin -releasing 
hormone) stimulation, with higher serum prolactin levels 
in patients who had not achieved pregnancy during the 
treatment for endometriosis [63-65]. 
On the other side, there are reports denying the 
connection of prolactin with endometriosis [66, 67].   
The influence of prolactin on fertility depends on se-
rum concentrations: as the level of prolactin increases, 
cycle abnormalities can progress sequentially from an in-
adequate luteal phase to intermittent anovulation with 
oligomenorrhoea to total anovulation and amenorrhoea. 
The consequence is infertility; therefore, it is crucial to 
control prolactin levels in hyperpolactinaemic infertile 
patients. 
Hyperprolactinaemia and Pregnancy 
It was reported that up to one- third of hyperolactinaemic 
patients achieved pregnancy in unstimulated cycles, 
though it must be noted that  most of the studies on that 
issue were conducted before the introduction of macropro-
lactin screening in routine clinical practice. Nevertheless, 
during the pregnancy of previous hyperprolactinaemic pa-
tients, there is  no increased percentage of spontaneous abor-
tions, nor increased perinatal mortality and morbidity. 
Breastfeeding is also allowed. There are no proven harm-
ful effects of dopamine agonists as bromocriptine and 
quinagolide, including teratogen effects and effects on fe-
tal osmoregulation. It was recommended that dopamine 
agonist therapy should be stopped when pregnancy is di-
agnosed [38]. 
Another concern during the pregnancy is a possible 
increase of the size of prolactinomas. The rise of mi-
croprolactinomas is extremely rare during the pregnancy: 
in 5% of all cases is asymptomatic, only in 2% of preg-
nant women the rising microprolactinoma could cause 
headache or visual disturbances [68, 69].      
Macroprolactinomas rise more often: 15% of pregnant 
women with macroprolactinomas have symptoms due to 
increased tumour: headache and visual disturbances [69, 
70, 71]. In such cases, it is possible to use NMR for 
diagnosing and commence the therapy with dopamine 
agonists which could control the rise of the tumour in  most 
of the patients [72, 73].  It is recommended that during the 
pregnancy follow-up should be based on the occurrence of 
the symptoms: NMR of the pituitary sella should be done 
in case of the appearance of the symptoms. Routine 
measurements of the PRL serum levels during the 
pregnancy are not necessary [38].   
A rare, but serious complication of the prolactinoma 
during the pregnancy is tumour necrosis and bleeding 
inside of the tumour, resulting in  insipid diabetes and 
pituitary insufficiency after the delivery [70].  
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Clinical experience showed that some previously 
hyperprolactinaemic patients after the delivery have 
normalized PRL serum levels and commenced 
spontaneous menstrual cycles without therapy, moreover 
get pregnant spontaneously, even they had many problems 
achieving  the first pregnancy. This is explained by 
spontaneous tumor necrosis during the pregnancy or 
sponatneous recovering of the primary dysfunction related 
to hyperprolactinaemia [74-76].  
Diagnostic Evaluation  
of Hyperprolactinaemia 
The diagnosis of hyperprolactinaemia is established by 
single measurements of serum PRL levels in two 
separated occasions (with serum sampling at least two 
hours apart from sleeping or eating). The serum should 
be obtained without excessive venipuncture stress and a 
level higher than the upper limit confirmed the diagnosis 
(> 530 mIU/l - according to World Health Organization 
Standard 84/500), as it was recommended previously [38, 
77, 78]. 
When the obtained level of prolactin raised any doubt, 
the sampling should be repeated on another day at 15–20 
min intervals to avoid prolactin pulsatile secretion.  
PRL serum levels higher than 250 ng/ml are sugges-
tive of the presence of a macroprolactinoma. PRL levels 
<100 ng/ml are associated with pseudoprolactinomas, 
drug-induced hyperprolactinaemia or systemic disease 
[79], but this  is not always the rule [80, 81]. 
In cases of highly elevated PRL serum levels "hook 
effect" should be considered, therefore PRL serum 
levels should be measured in diluted blood serum. 
Clinically, such cases are present with symptoms of 
hyperprolactinaemia and falsely low PRL serum levels in 
undiluted spacemen [82, 83].  
Diagnostic evaluation of hyperprolactinaemia includes: 
medical history, physical examination, assessing the clinical 
features and laboratory findings (especially PRL serum 
levels), as well as imaging studies of the pituitary and 
sella turcica (preferably pituitary NMR). Screening for 
macroprolactinaemia is also desirable, in asymptomatic 
patients is highly recommended [38].  
Taking a proper medical history is essential in cases 
of pharmacological hyperprolactinaemia, but the con-
comitance of a pathologic cause should be always kept in 
mind. PRL measurements should be repeated after the 
discontinuation of the medication after 3 to 4 days (cor-
roborated by a psychiatrist). If the discontinuing of the 
medication is not possible, pituitary NMR should be per-
formed. In cases of confirmed drug-induced hyperpolac-
tinaemia, the alternative medication should be tried, if 
possible [38, 84].    
A similar situation is in the case of the rare concomi-
tance of primary hypothyroidism and prolactinomas, 
which should be suspected when high PRL serum levels 
persist despite normalization of thyroid function [80].  
Macroprolactinaemia 
In the case of obvious discrepancy between high PRL serum 
levels and the absence of clinical symptoms and signs of hy-
perprolactinaemia, macroprolactinaemia should be sus-
pected. 
Macroprolactinaemia is a condition where 60% of cir-
culating PRL is made of macroprolactin, form of circu-
lating PRL with lesser biological activity.   
In patients with hyperprolactinaemia about 25% have 
macroprolactinaemia (ranges from 10% to 35%) [85-89] 
but the precise prevalence of macroprolactinaemia in 
hyperprolactinaemic and the general population is still 
unknown [90].  
The gold standard for diagnosing macroprolactinae-
mia is gel-filtration chromatography, which is expensive 
and time-consuming, so polyethylene glycol (PEG) se-
rum precipitation is used as a screening method. The di-
agnosis of macroprolactinaemia is made when a PEG 
precipitation ratio is greater than 60% or recovery of less 
than 40% after PEG [91].   
Macroprolactin is not considered to have significant 
biological activity, but it retains partial or total immuno-
reactivity with anti-PRL antibodies used in commercial 
immunoassays. Detection of macroprolactin is clinically 
important to avoid incorrect diagnosis and unnecessary 
investigations.  
Nevertheless, later investigations revealed that some 
patients with macroprolactinaemia could have symptoms 
of hyperprolactinaemia or abnormal findings of the 
anterior pituitary, but in far lesser degree compared with 
patients with true hyperprolactinaemia [93]. Therefore, 
the presence of menstrual disorders, galactorrhoea 
,and/or infertility in hyperprolactinaemic patients does 
not exclude macroprolactinaemia. Galactorrhoea was 
found in 46%, menstrual disorders in 39%, infertility as-
sociated with galactorrhoea or with menstrual irregulari-
ties  in 28% of macroprolactiaemic patients [85].  
Some authors recommend that the screening for 
macroprolactiaemia should be done in all hyperprolacti-
naemic patients [90, 93], the others consider that it is 
mostly indicated for asymptomatic patients, in apparent 
idiopathic hyperprolactinaemia and  any patients without 
an obvious cause for the hyperprolactinaemia [46].  
Idiopathic Hyperprolactinaemia 
Idiopathic hyperprolactinaemia is defined as hyperpro-
lactinaemia of unknown etiology, ie when its secondary 
causes have been ruled out and pituitary nuclear magnetic 
resonance (NMR) is normal [77, 94, 95]. The prevalence 
of idiopathic hyperpolactinaemia varies from 3.6% 
among patients with hyperpolactinaemia, to as much as 
87.97% in hyperprolactinaemic infertile women [88]. 
Possible explanations for idiopathic hyperprolacti-
naemia include: immunological causes (formation of an-
tipituitary antibodies) [96], the existence of very small 
microprolactinomas that could not be detected with cur-
rent imaging techniques [78], or differences in prolactin 
receptor function (novel hypothesis) [97]. 
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Treatment of Hyperprolactinaemia  
in Women 
Indications for lowering high serum PRL levels are: 
anovulation and subsequent infertility, treatment of 
galactorrhoea that represent a problem to the patient, and 
treatment of the manifestation of the hypoestrogenic state 
to prevent osteoporosis and improve the quality of life.   
Treatment options for hyperprolactinaemia are listed 
in Table 3. 
Table 3 Treatment options for hyperprolactinaemia in 
clinical practice 
Dopamine agonist 
▪ ergot derivates: bromocriptine, cabergoline, 
pergolide, lisuride etc. 
▪ nonergot derivate: quinagolide  
Surgical treatment for prolactinomas 
Dopamine agonists are the first line for the medical 
treatment of hyperprolactinaemia in women with anovu-
lation as sole reason for infertility, being successful in re-
storing ovulation in up to 80% of infertile patients with 
hyperprolactinaemia.  
Bromocriptine is safe for the treatment of the patients 
with hyperprolactinaemic anovulation and infertility, due 
to its safety in early pregnancy. Bromocriptine has been 
used for almost 50 years with no reported fetal harmful 
effects. The long term follow-up of the children born by 
mothers taking bromocriptine in early pregnancy showed 
the absence of any adverse effects [98].   
In our practice, we start bromocriptine with a dose of 
1.25 mg/day, or even less, before sleeping due to side ef-
fects. It can be titrated to a maximum of 7.5 mg/day for 
the treatment of hyperprolacatinaemic anovulation and 
infertility. The half-life of bromocriptine is about 6 hours, 
so we consider that daily dose should be divided into two 
or three smaller doses, which offer better control of cir-
cadian variations of prolactin serum levels, as well as bet-
ter control of nocturnal prolactin levels. Side effects of 
bromocriptine included nausea, dizziness, headache, and 
postural hypotension, as common side effects of dopa-
mine agonists .  
The unusual side effects of the bromocriptine therapy 
are hallucinations due to similarity of the bromocriptine 
molecule to LSD (in 1-2%). We have seen such effects in 
our patients: one had scintillations and another had seen 
a fire on the electric stow. The more often problem is pos-
sibility of low concentration during the bromocriptine 
therapy and the patient should be warned on such effect.   
Cabergoline is also an effective dopamine agonist. It 
was reported that cabergoline is better tolerated and more 
successful in achieving pregnancy than bromocriptine 
[99, 100].  
The half-life of the cabergoline is 65 hours, so it is 
administered once (0.8 mg) or twice (0.4 mg) a week, 
with a maximal dose of 1–2 mg/week. The incipient dose 
of cabergoline could be as small as 0.25 mg twice a week, 
with a gradually increase to 0.5 mg twice a week 
according to the effects of therapy. It is more comfortable 
for the patient than bromocriptine. Cabergoline is safe 
during early pregnancy according to fetal anomalies 
[101-103], but the studies of other possible effects on fe-
tal development are still missing.  The problem with 
cabergoline is also a development of cardiac valvular dis-
ease due to possible thickened of  cardiac valves caused 
by cabergoline effects on mitogenesis and fibroblast pro-
liferation, which has been seen in patients with Parkin-
son’s disease taking higher doses of cabergoline 
(4 mg/day – much higher than the dose for hyperprolacti-
naemia) [104, 105].  
Nevertheless, the development of constrictive peri-
carditis during cabergoline therapy for hyperprolactinae-
mia (and smaller doses) has been also reported, so echo-
cardiography in 6 to 12 months intervals is mandatory for 
patients receiving cabergoline [106]. 
Quinagolide, a nonergot dopamine agonist, is also 
successful in the treatment of infertile patients with hy-
perprolactinaemia [107].  
Quinagolide has a higher affinity to D2 receptors and 
a longer half-life (22 hours) than bromocriptine, so it is 
administered once a day [108]. The initial dose is 25 – 50 
micrograms once a day; with a gradual increase to 75 mi-
crograms once a day. 
Quinagolide is well tolerated and safe in early preg-
nancy [109]. 
In patients with prolactinomas, dopamin agonists are 
successful in achieving normal PRL serum levels in 71% 
and tumour shrinkage in 80% of all cases [110]. In the case 
of the rising prolactinoma, it was recommended to use  
cabergoline in preference to other dopamine agonists 
because it has a higher efficacy in normalizing PRL levels, 
as well as better results in pituitary tumour shtrinkage. 
Cabergoline greater efficacy may be explained by its higher 
affinity for dopamine receptor binding sites [38].       
Surgical treatment (nasosphenoidal approach) is  
reserved for growing macroprolactinomas or those 
associated with neural manifestations. Microprolactinomas 
do not need such interventions. Moreover, it was 
recommended that asymptomatic microprolactinomas 
should not be treated with dopamine agonists. It was 
suggested that patients with amenorrhoea and 
microadenoma should be treated with dopamine agonists or 
oral contrarceptives [38]. The growth of the tumour during 
the therapy with oral contraceptives is extremely rare, but 
the patient should be warned on the symptoms and 
possibility of the rise of the intracranial pressure [68, 69, 74].  
Conclusion 
Hyperoprlactinaemia is one of the most frequent causes of 
anovulation, resulting in infertility and hypoestrogenic 
state with consequences on overall women’s health. There 
are numerous etiological  factors of hyperprolactinaemia, 
therefore, taking proper medical history and clinical 
assessment are crucial for correct differential diagnosis 
and proper therapy. Macroprolactinaemia and "hook 
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effect" must be considered in the evaluation of 
hyperprolactinaemia. Indications for the treatment of 
hyperprolactinaemic female patient are infertility, 
galactorrhoea that represents the problem for the patient, 
and hypoestrogenic state. Dopamine agonists are 
successful in lowering PRL serum levels and restoring 
ovulation and represent the main option for the treatment 
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